Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kathleen Corey, M.D.

Co-Author

This page shows the publications co-authored by Kathleen Corey and Raymond Chung.
Connection Strength

9.424
  1. Obstructive Sleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology. Dig Dis Sci. 2015 Aug; 60(8):2523-8.
    View in: PubMed
    Score: 0.657
  2. The absence of obstructive sleep apnea may protect against non-alcoholic fatty liver in patients undergoing bariatric surgery. PLoS One. 2013; 8(5):e62504.
    View in: PubMed
    Score: 0.575
  3. Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2012 Jun; 10(6):651-6.
    View in: PubMed
    Score: 0.528
  4. Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers. Infect Control Hosp Epidemiol. 2009 Oct; 30(10):1000-5.
    View in: PubMed
    Score: 0.449
  5. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology. 2009 Oct; 50(4):1030-7.
    View in: PubMed
    Score: 0.449
  6. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat. 2010 Mar; 17(3):201-7.
    View in: PubMed
    Score: 0.444
  7. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 2009 May; 29(5):748-53.
    View in: PubMed
    Score: 0.429
  8. Treating difficult-to-treat hepatitis C virus infection: we may still need to push the ribavirin envelope. Gastroenterology. 2007 Dec; 133(6):2062-3.
    View in: PubMed
    Score: 0.395
  9. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol. 2006 Oct; 4(10):1278-82.
    View in: PubMed
    Score: 0.362
  10. Expert Panel Review on Non-Alcoholic Fatty Liver Disease in Persons With HIV. Clin Gastroenterol Hepatol. 2020 Oct 16.
    View in: PubMed
    Score: 0.241
  11. Low Complement C4 Predicts Improvement of Kidney Function After Direct-Acting Antiviral Therapy for Hepatitis C Virus. Hepatol Commun. 2020 Aug; 4(8):1206-1217.
    View in: PubMed
    Score: 0.235
  12. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. Am J Transplant. 2020 06; 20(6):1619-1628.
    View in: PubMed
    Score: 0.230
  13. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019 12; 17(13):2776-2784.e4.
    View in: PubMed
    Score: 0.218
  14. Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial. Aliment Pharmacol Ther. 2019 05; 49(9):1205-1213.
    View in: PubMed
    Score: 0.216
  15. Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol. 2018 05 15; 259:198-204.
    View in: PubMed
    Score: 0.204
  16. Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction. Obesity (Silver Spring). 2017 08; 25(8):1313-1316.
    View in: PubMed
    Score: 0.193
  17. MELD-Na score predicts incident major cardiovascular events, in patients with nonalcoholic fatty liver disease (NAFLD). Hepatol Commun. 2017 Jul; 1(5):429-438.
    View in: PubMed
    Score: 0.190
  18. Intermittent hypoxia is a proinflammatory stimulus resulting in IL-6 expression and M1 macrophage polarization. Hepatol Commun. 2017 06; 1(4):326-337.
    View in: PubMed
    Score: 0.190
  19. Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. Clin Transplant. 2016 Apr; 30(4):452-60.
    View in: PubMed
    Score: 0.175
  20. Using an Electronic Medical Records Database to Identify Non-Traditional Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2016 05; 111(5):671-6.
    View in: PubMed
    Score: 0.175
  21. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Dig Dis Sci. 2016 07; 61(7):2108-17.
    View in: PubMed
    Score: 0.174
  22. Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol. 2015 Oct 08; 6:e114.
    View in: PubMed
    Score: 0.170
  23. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond). 2015; 47(12):924-9.
    View in: PubMed
    Score: 0.169
  24. Host genetics predict clinical deterioration in HCV-related cirrhosis. PLoS One. 2014; 9(12):e114747.
    View in: PubMed
    Score: 0.161
  25. Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement. Radiology. 2015 Mar; 274(3):888-96.
    View in: PubMed
    Score: 0.160
  26. Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile. Lipids Health Dis. 2014 Jun 21; 13:100.
    View in: PubMed
    Score: 0.156
  27. Advanced disease, diuretic use, and marital status predict hospital admissions in an ambulatory cirrhosis cohort. Dig Dis Sci. 2014 Jan; 59(1):174-82.
    View in: PubMed
    Score: 0.147
  28. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One. 2012; 7(2):e27144.
    View in: PubMed
    Score: 0.132
  29. Hepatocellular carcinoma screening rates vary by etiology of cirrhosis and involvement of gastrointestinal sub-specialists. Dig Dis Sci. 2011 Nov; 56(11):3316-22.
    View in: PubMed
    Score: 0.127
  30. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int. 2011 Mar; 31(3):330-9.
    View in: PubMed
    Score: 0.119
  31. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology. 2021 Feb; 73(2):548-559.
    View in: PubMed
    Score: 0.062
  32. Association Between Liver Fat and Bone Density is Confounded by General and Visceral Adiposity in a Community-Based Cohort. Obesity (Silver Spring). 2021 Mar; 29(3):595-600.
    View in: PubMed
    Score: 0.062
  33. Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2021 Jan 23; 106(2):e520-e533.
    View in: PubMed
    Score: 0.061
  34. Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Hepatol Commun. 2021 Jan; 5(1):133-143.
    View in: PubMed
    Score: 0.061
  35. Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. Hepatology. 2020 11; 72(5):1819-1837.
    View in: PubMed
    Score: 0.060
  36. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020 08 20; 5(16).
    View in: PubMed
    Score: 0.060
  37. Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated NAFLD. Clin Infect Dis. 2020 Apr 09.
    View in: PubMed
    Score: 0.058
  38. Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease. Ultrasound Med Biol. 2020 Apr; 46(4):972-980.
    View in: PubMed
    Score: 0.057
  39. Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts. J Hepatol. 2020 06; 72(6):1062-1069.
    View in: PubMed
    Score: 0.057
  40. Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. Cell Metab. 2020 02 04; 31(2):406-421.e7.
    View in: PubMed
    Score: 0.057
  41. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019 12; 6(12):e821-e830.
    View in: PubMed
    Score: 0.056
  42. Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey Study. Liver Transpl. 2019 06; 25(6):859-869.
    View in: PubMed
    Score: 0.054
  43. Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease. Clin Gastroenterol Hepatol. 2019 11; 17(12):2592-2599.
    View in: PubMed
    Score: 0.054
  44. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol. 2018 12 01; 4(12):1683-1690.
    View in: PubMed
    Score: 0.053
  45. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis. 2018 09 22; 218(9):1394-1403.
    View in: PubMed
    Score: 0.052
  46. Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity. Hepatol Commun. 2018 Jul; 2(7):786-797.
    View in: PubMed
    Score: 0.052
  47. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol. 2018 Nov 01; 270:245-252.
    View in: PubMed
    Score: 0.051
  48. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology. 2018 05; 67(5):1797-1806.
    View in: PubMed
    Score: 0.050
  49. Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV)-Positive and HCV-Negative Men at Various Lipid Levels: Results From ERCHIVES. Clin Infect Dis. 2017 Aug 15; 65(4):557-565.
    View in: PubMed
    Score: 0.048
  50. Validation of Shear Wave Elastography Cutoff Values on the Supersonic Aixplorer for Practical Clinical Use in Liver Fibrosis Staging. Ultrasound Med Biol. 2017 06; 43(6):1125-1133.
    View in: PubMed
    Score: 0.047
  51. Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. Hepatology. 2017 04; 65(4):1156-1164.
    View in: PubMed
    Score: 0.047
  52. Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. Cell Metab. 2016 12 13; 24(6):848-862.
    View in: PubMed
    Score: 0.046
  53. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Dig Dis Sci. 2016 12; 61(12):3425-3435.
    View in: PubMed
    Score: 0.046
  54. A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions. Sci Rep. 2015 Dec 15; 5:18277.
    View in: PubMed
    Score: 0.043
  55. Lipid metabolite profiling identifies desmosterol metabolism as a new antiviral target for hepatitis C virus. J Am Chem Soc. 2012 Apr 25; 134(16):6896-9.
    View in: PubMed
    Score: 0.033
  56. A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients. Dig Dis Sci. 2010 Sep; 55(9):2629-35.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.